Oncolytic Virus Cancer Therapy Pipeline Analysis, 2024 - Showing Promise with Over 120 Companies and 125 Drugs in Development
June 14, 2024 06:51 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The field of oncolytic virus...
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024 08:00 ET
|
Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET
|
Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight - A USD 1.50 Billion+ Market Opportunity by 2030
May 14, 2024 08:50 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering....
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
May 06, 2024 10:21 ET
|
The Benchmark Company
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday &...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight
January 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight Nanomedicine is experiencing heightened demand,...
Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight
January 02, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biopharmaceuticals Global Market is Expected to Surpass 700 Billion Mark by 2028, Assesses DelveInsight The demand for biopharmaceuticals is...
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET
|
Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer